File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Anticancer nanometre-biomissiles carrying a leucine insulator and an antibody complementarity-determining region

TitleAnticancer nanometre-biomissiles carrying a leucine insulator and an antibody complementarity-determining region
Authors
Keywordsantibody complementarity-determining region
Anticancer nanometre-biomissiles
consensus peptide sequences
leucine insulator
mouse model
Issue Date2021
Citation
Current Science, 2021, v. 120, n. 1, p. 177-185 How to Cite?
AbstractThe tumour specificities and potency of miniaturized cancer targeting peptides are among the major issues of current cancer research. Over 100 peptides were evaluated in this study. According to the observations, leucine could sustain the antibacterial and anticancer efficacy of (leucine/lysine) n ((L/K)n) peptides across different assay conditions, whereas (valine/lysine) n ((V/K)n) and (isoleucine/lysine) n ((I/K)n) peptides were less effective. Tumour targeting peptides, consisting of a leucine/lysine peptide and an antibody complementarity-determining region (CDR) fragment against CD47 receptor separated by a leucine4 insulator, eradicated 100% of the lung cancer A549 cells at 100 p.m concentration after 24 h of incubation. It also inhibited tumour growth in a mouse model of colon cancer cells, showing extensive apoptosis at the end of the treatment. Our data suggest that leucine insulators could be effective spacers in the design of targeted or plurispecific peptide drugs given the lack of ϭ-ϭhyperconjugation on ß-carbon and the lack of strong van der Waals interactions between the side group and the carbonyl group. Significant reduction of hemolysis by P45-3 with terminal alanine replacement on peptide P129 suggests that biosafety attribute of a peptide can be substantially improved.
Persistent Identifierhttp://hdl.handle.net/10722/315344
ISSN
2023 Impact Factor: 1.1
2023 SCImago Journal Rankings: 0.240
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorXing, Meng-
dc.contributor.authorLi, Xiaoxia-
dc.contributor.authorAn, Shanshan-
dc.contributor.authorLan, Chongfeng-
dc.contributor.authorFu, Min-
dc.contributor.authorShi, Yunfan-
dc.contributor.authorHuang, Yan-
dc.contributor.authorTang, Man-
dc.contributor.authorWan, Yulin-
dc.contributor.authorWang, Yuchuan-
dc.contributor.authorPeng, Jingli-
dc.contributor.authorWang, Kai-
dc.contributor.authorYe, Zi Wei-
dc.contributor.authorWeng, Shaoping-
dc.contributor.authorLiu, Qiuyun-
dc.contributor.authorHe, Jianguo-
dc.contributor.authorZhou, Wenliang-
dc.date.accessioned2022-08-05T10:18:32Z-
dc.date.available2022-08-05T10:18:32Z-
dc.date.issued2021-
dc.identifier.citationCurrent Science, 2021, v. 120, n. 1, p. 177-185-
dc.identifier.issn0011-3891-
dc.identifier.urihttp://hdl.handle.net/10722/315344-
dc.description.abstractThe tumour specificities and potency of miniaturized cancer targeting peptides are among the major issues of current cancer research. Over 100 peptides were evaluated in this study. According to the observations, leucine could sustain the antibacterial and anticancer efficacy of (leucine/lysine) n ((L/K)n) peptides across different assay conditions, whereas (valine/lysine) n ((V/K)n) and (isoleucine/lysine) n ((I/K)n) peptides were less effective. Tumour targeting peptides, consisting of a leucine/lysine peptide and an antibody complementarity-determining region (CDR) fragment against CD47 receptor separated by a leucine4 insulator, eradicated 100% of the lung cancer A549 cells at 100 p.m concentration after 24 h of incubation. It also inhibited tumour growth in a mouse model of colon cancer cells, showing extensive apoptosis at the end of the treatment. Our data suggest that leucine insulators could be effective spacers in the design of targeted or plurispecific peptide drugs given the lack of ϭ-ϭhyperconjugation on ß-carbon and the lack of strong van der Waals interactions between the side group and the carbonyl group. Significant reduction of hemolysis by P45-3 with terminal alanine replacement on peptide P129 suggests that biosafety attribute of a peptide can be substantially improved.-
dc.languageeng-
dc.relation.ispartofCurrent Science-
dc.subjectantibody complementarity-determining region-
dc.subjectAnticancer nanometre-biomissiles-
dc.subjectconsensus peptide sequences-
dc.subjectleucine insulator-
dc.subjectmouse model-
dc.titleAnticancer nanometre-biomissiles carrying a leucine insulator and an antibody complementarity-determining region-
dc.typeArticle-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.18520/cs/v120/i1/177-185-
dc.identifier.scopuseid_2-s2.0-85100050588-
dc.identifier.volume120-
dc.identifier.issue1-
dc.identifier.spage177-
dc.identifier.epage185-
dc.identifier.isiWOS:000606363600043-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats